The reduction in the Framingham HARD CHD risk score by 29% is similar to that previously described in patients with plain obesity [23] and occurred in parallel to a simultaneous diminution in the use of insulin by 35% and of OADs other than metformin and DPP-4 inhibitors up to 99%. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.